Qiagen (NYSE:QGEN) Issues FY 2024 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.160- for the period, compared to the consensus earnings per share estimate of 2.120. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of 2.160.

Qiagen Trading Down 0.2 %

Qiagen stock traded down $0.09 during trading hours on Friday, reaching $45.42. The company had a trading volume of 847,455 shares, compared to its average volume of 1,245,056. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.45. Qiagen has a 12-month low of $34.74 and a 12-month high of $46.55. The company has a 50-day moving average price of $42.85 and a 200 day moving average price of $43.04. The firm has a market cap of $10.36 billion, a price-to-earnings ratio of 30.46, a P/E/G ratio of 3.19 and a beta of 0.40.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm had revenue of $496.00 million for the quarter, compared to analysts’ expectations of $495.45 million. During the same quarter last year, the business earned $0.53 earnings per share. The business’s revenue was down .2% on a year-over-year basis. Equities analysts forecast that Qiagen will post 2.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on QGEN shares. Robert W. Baird increased their target price on shares of Qiagen from $49.00 to $52.00 and gave the stock an outperform rating in a report on Friday, August 2nd. Wolfe Research upgraded Qiagen from a peer perform rating to an outperform rating and set a $50.00 price objective for the company in a report on Thursday, June 27th. JPMorgan Chase & Co. boosted their target price on Qiagen from $52.00 to $54.00 and gave the company an overweight rating in a research note on Tuesday, June 18th. Finally, Stifel Nicolaus decreased their target price on Qiagen from $55.00 to $45.00 and set a hold rating for the company in a report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $51.10.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.